We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+10.92%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$43.9B
AUM Growth
+$2.87B
(+7%)
Cap. Flow
-$890M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
13.25%
Holding
2,343
New
170
Increased
997
Reduced
1,015
Closed
150
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$111M |
| 2 |
Verizon
VZ
|
+$103M |
| 3 |
AT&T
T
|
+$103M |
| 4 |
Kroger
KR
|
+$97.1M |
| 5 |
3M
MMM
|
+$92.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$138M |
| 2 |
Tesla
TSLA
|
+$110M |
| 3 |
JPMorgan Chase
JPM
|
+$103M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$89.4M |
| 5 |
Apple
AAPL
|
+$85.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 16.25% |
| 3 | Financials | 11.85% |
| 4 | Industrials | 11.44% |
| 5 | Consumer Discretionary | 10.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2101
Verra Mobility
VRRM
$720M
| $160K | ﹤0.01% |
11,536
+212
| +2% | +$3.22K |
|
2102
Enovix
ENVX
$1.01B
| $155K | ﹤0.01% |
+14,227
| New | +$175K |
|
2103
Braskem
BAK
$889M
| $152K | ﹤0.01% |
16,544
-1,675
| -9% | -$18.6K |
|
|
VLDR
2104
DELISTED
Velodyne Lidar, Inc. Common Stock
VLDR
| $150K | ﹤0.01% |
203,144
-610,268
| -75% | -$577K |
|
|
ARIS
2105
DELISTED
Aris Water Solutions
ARIS
| $149K | ﹤0.01% |
+10,323
| New | +$159K |
|
2106
MBIA
MBI
$257M
| $148K | ﹤0.01% |
11,523
+478
| +4% | +$5.46K |
|
2107
NeoGenomics
NEO
$2.14B
| $143K | ﹤0.01% |
15,529
-21,147
| -58% | -$197K |
|
2108
Adicet Bio
ACET
$75.9M
| $142K | ﹤0.01% |
996
+214
| +27% | +$53.4K |
|
|
AMPS
2109
DELISTED
Altus Power
AMPS
| $142K | ﹤0.01% |
21,845
+8,401
| +62% | +$68.6K |
|
2110
PLAYSTUDIOS Inc
MYPS
$86.3M
| $142K | ﹤0.01% |
36,590
+653
| +2% | +$2.62K |
|
2111
Blend Labs
BLND
$357M
| $141K | ﹤0.01% |
+97,909
| New | +$175K |
|
|
DZSI
2112
DELISTED
DZS Inc. Common Stock
DZSI
| $140K | ﹤0.01% |
+11,067
| New | +$141K |
|
2113
Nordic American Tanker
NAT
$1.33B
| $138K | ﹤0.01% |
+45,144
| New | +$146K |
|
2114
Ooma
OOMA
$593M
| $138K | ﹤0.01% |
10,134
-1,388
| -12% | -$20.5K |
|
|
CMAX
2115
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $135K | ﹤0.01% |
+1,236
| New | +$185K |
|
|
SRTA
2116
Strata Critical Medical Inc
SRTA
$525M
| $135K | ﹤0.01% |
+37,776
| New | +$161K |
|
|
STKL
2117
DELISTED
SunOpta
STKL
| $135K | ﹤0.01% |
16,012
-349
| -2% | -$3.3K |
|
2118
C3.ai
AI
$1.62B
| $134K | ﹤0.01% |
+12,353
| New | +$155K |
|
2119
Opendoor
OPEN
$3.38B
| $131K | ﹤0.01% |
117,457
+94,103
| +403% | +$180K |
|
2120
Definitive Healthcare
DH
$73.7M
| $131K | ﹤0.01% |
+12,009
| New | +$154K |
|
|
IMGN
2121
DELISTED
Immunogen Inc
IMGN
| $130K | ﹤0.01% |
26,176
| – | – |
|
2122
Heron Therapeutics
HRTX
$63.4M
| $128K | ﹤0.01% |
51,360
-1,908
| -4% | -$6.15K |
|
2123
Rithm Capital
RITM
$5.65B
| $128K | ﹤0.01% |
15,614
+764
| +5% | +$6.38K |
|
|
QUOT
2124
DELISTED
Quotient Technology Inc
QUOT
| $127K | ﹤0.01% |
37,029
-203,311
| -85% | -$575K |
|
|
TELL
2125
DELISTED
Tellurian Inc.
TELL
| $127K | ﹤0.01% |
75,355
-8,809
| -10% | -$22.1K |
|
Similar funds
VGA
AQR Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, AQR Capital Management held 2,343 positions worth $43.9B, up 7% from $41B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
AQR Capital Management's Q4 2022 filing shows 170 new, 997 increased, 1,015 reduced and 150 closed positions. Its largest new stake was Generac Holdings: 310,080 shares worth $30.5M. The largest sale was Gilead Sciences, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q4 2022 buy was Generac Holdings: 310,080 shares worth $30.5M.
- AQR Capital Management added most to Humana in Q4 2022, an estimated $111M increase.
- AQR Capital Management's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $138M.
- AQR Capital Management fully exited Abiomed Inc in Q4 2022, selling an estimated $22.4M.
- AQR Capital Management's ten largest holdings make up 13% of its $43.9B portfolio in Q4 2022.
- AQR Capital Management opened 170 new positions and closed 150 in Q4 2022.
- AQR Capital Management's portfolio value rose 7% quarter-over-quarter to $43.9B.
Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.